Founded in October 2000, Zhejiang Guobang Pharmaceutical is a core enterprise of the Guobang Pharmaceutical Group. The company's core is in pharmaceutical manufacturing technology and it is engaged in the R&D, production, and operation for pharmaceutical and veterinary APIs and is a well-established manufacturer of synthetic APIs in China. The company's primary products are quinolones and macrolides and it is the world's leading producer of azithromycin, clarithromycin, roxithromycin, ciprofloxacin, enrofloxacin and marbofloxacin. Its production capacity and market share are above 35% in both the Chinese and international markets and its products are exported to 112 countries and regions, covering 6.5 billion people. Its sales network covers all regions of China and the US and European markets.

The company is a national high-tech enterprise, with a national-level postdoctoral research

station, a province-level pharmaceutical research institute, and a province-level enterprise technology center. It has received National Production Safety Standardization Certification, ISO 9001：2008 quality management certification and ISO 14001 environmental management system certification. All products have received national pharmaceutical and veterinary GMP certification, and all main products have received EUGMP, FDA, PMDA, ANVISA, MFDS and other certifications.